Every 10-Q that Ibio (IBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBIO filings page.
iBio, Inc. reported no revenue for the quarter ended March 31, 2026 and a net loss of $7.7M, widening from $4.9M a year earlier, as it continues to invest in obesity and cardiometabolic antibody programs.
For the nine months, the net loss was $22.4M versus $13.2M in the prior-year period, driven by higher research and development and general and administrative expenses plus a $5.0M impairment of an oncology intangible asset. Operating cash outflow was $17.0M.
Liquidity strengthened significantly: cash and cash equivalents were $47.6M and investments in debt securities were $27.2M, for total liquid financial assets of about $74.8M. This reflects an underwritten public offering of approximately $50M, a private placement of approximately $26M, and about $13.8M of warrant exercise proceeds during the period, plus additional warrant exercises after quarter-end. The company now believes this cash is sufficient to fund operations for at least 12 months from the financial statement issuance date.
iBio remains a preclinical-stage biotechnology company using its AI Drug Discovery Platform to develop precision antibodies, with lead obesity-related candidates IBIO-600 and IBIO-610 expected to enter first-in-human trials in calendar 2026 and the first half of 2027, respectively.
iBio, Inc. reported a larger net loss while significantly strengthening its balance sheet as it advances its AI-driven obesity pipeline. For the three months ended December 31, 2025, the company generated no revenue, versus $200,000 a year earlier, and posted a net loss of $8.99 million as research and development and general and administrative expenses more than doubled.
For the six-month period, revenue was $100,000 and the net loss widened to $14.71 million. Operating cash outflows were $10.91 million, but financing activities, including sales of pre-funded warrants and common stock, provided $55.49 million, lifting cash and cash equivalents to $28.67 million and investments in debt securities to $24.03 million as of December 31, 2025.
The company recorded a $2.5 million impairment on an oncology intangible asset as it sharpened its focus on cardiometabolic and obesity antibodies. With approximately $52.7 million in cash and investments at period end and an additional $26 million raised in a January 2026 private placement, iBio believes it can fund operations for at least 12 months as it prepares IBIO-600 for Phase 1a trials in the first half of 2026 and targets first-in-human studies for IBIO-610 in early 2027.
iBio, Inc. filed an amended Form 10-Q/A mainly to correct the CEO Section 906 certification language in Exhibit 32.1; all financial and business disclosures from the original quarterly report for the three months ended September 30, 2025 remain unchanged.
The company is a preclinical biotech using AI and machine learning to design precision antibodies for obesity and cardiometabolic diseases, with lead candidate IBIO-610, a long-acting Activin E–inhibiting antibody, targeted for first human trials in early 2027. For the quarter, iBio generated $100,000 of collaboration revenue and recorded a net loss of $5.7 million, or $0.11 per share, as R&D spending rose to support its pipeline. A recent underwritten public offering and related pre-funded warrants provided approximately $50 million of gross proceeds, lifting cash, cash equivalents and investments in debt securities to about $49.6 million, which management believes is sufficient to fund operations for at least 12 months from the filing date.
iBio, Inc. reported its quarterly results for the period ended September 30, 2025. The company generated $100,000 in revenue, with operating expenses of $6.1 million (R&D $3.6 million; G&A $2.5 million), leading to an operating loss of $5.95 million and a net loss of $5.72 million (loss per share $0.11).
Liquidity strengthened following an August 2025 financing, reflected in $28.1 million of cash and cash equivalents and $21.5 million of available‑for‑sale debt securities, totaling approximately $49.6 million at quarter‑end. Stockholders’ equity increased to $56.0 million. Shares outstanding were 20,254,599 as of September 30, 2025.
The company recognized collaboration revenue and reported contract liabilities of $1.15 million. iBio continues to build a preclinical pipeline focused on obesity and cardiometabolic diseases, with IBIO‑610 (Activin E) highlighted as a lead asset. Management states current liquidity is sufficient to fund operations for at least 12 months from the filing date.